Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
The FDA has approved baxdrostat (Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2026-06-25
- DOI
- https://doi.org/10.58347/tml.2026.1758a
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00